Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PZ HTL SA
GLOBETECH PUBLISHING LLC

European Biopharmaceutical Companies Launch Anticancer Drug Project

By BiotechDaily International staff writers
Posted on 12 Nov 2013
Two European biopharmaceutical companies are joining forces in an intensive effort to develop a new series of anticancer drugs.

ZoBio (Leiden, The Netherlands) will be applying its proprietary TINS technology to screen a library of drug fragments for specific binding to the desired conformation of the target protein.

TINS is a powerful approach that has been validated on a wide range of targets including viral proteins, proteases, kinases, protein-protein interaction targets, molecular chaperones, and membrane proteins. TINS uses a single sample of the target and a reference protein that have been immobilized on Sepharose-based resin. Fragments to be assayed for binding are injected as mixtures of between three and nine compounds. Binding is detected by a reduction in the height of the NMR signals of a compound that specifically binds to the target. Comparison of the NMR spectra of the fragments in the presence of the target and reference proteins directly reveals the identity of the binding ligand.

ZoBio offers its proprietary TINS technology for ligand screening studies on its own, highly validated fragment library or the customer’s. A typical TINS discovery and characterization/validation project is completed in one to two months.

ZoBio's partner in the new project is Actelion Ltd. (Allschwil, Switzerland), a company that has demonstrated global leadership in the field of pulmonary arterial hypertension (PAH) therapy. Actelion is known for a strong and effective worldwide specialty commercial organization, a highly productive discovery capability, and a unique company culture that focuses on delivering innovative medicines that improve patient’s lives.

Dr. Gregg Siegal, CSO of ZoBio said, “We are proud that Actelion, a company with such success in bringing innovative drugs to the market, has selected ZoBio as a partner. We feel that this collaboration has a great chance to succeed where others have failed.”

Related Links:

ZoBio
Actelion Ltd.



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This novel, flexible film that can react to light is a promising step toward an artificial retina (Photo courtesy of the American Chemical Society).

Novel Nanofilm May Be Artificial Retina Precursor

Researchers have used advanced nanotechnology techniques to develop a light-sensitive film that has potential for future artificial retina applications. Investigators at the Hebrew University of Jerusalem... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.